Skip to main content

Table 1 Patient and lesion characteristics

From: MRI background parenchymal enhancement, fibroglandular tissue, and mammographic breast density in patients with invasive lobular breast cancer on adjuvant endocrine hormonal treatment: associations with survival

Patients

Total (n = 298)

First recurrence (n = 50)

Second recurrence (n = 6)

Death (n = 21)*

Histology

 Lobular

229

38

3

14

 Pleomorphic

31

8

2

6

 Mixed

38

4

1

1

Focality

 Unifocal

122

17

1

10

 Bifocal/multifocal

175

33

5

10

 Unknown

1

0

0

1

Tumor diameter

 2–19 mm

212

35

3

8

 20–49 mm

71

8

1

7

 > 50 mm

15

7

2

6

Axillary load

 None

192

26

3

7

 1–3

84

13

1

3

 > 4

21

11

2

10

 Unknown

1

0

0

1

Hormone receptor

 ER/PR+ HER2−

292

49

6

21

 HER2+

6

1

0

0

Endocrine treatment

 AI

139

19

3

10

 SERMS

156

31

3

11

 LHRH analogues

3

   

Endocrine treatment duration

 ≤ 5 years

145

32

4

16

 ≥ 6 years

153

18

2

5

Concurrent chemotherapy and radiotherapy

 Chemotherapy

193

38

5

19

 Radiotherapy

200

36

5

14

 Chemo + radio

126

28

4

12

 No chemo-/radiotherapy

31

4

0

0

  1. Abbreviations: AI aromatase inhibitors, SERMS selective estrogen receptor modulators, LIRH luteinizing hormone-releasing hormone
  2. *Eight patients’ death was not directly related to breast cancer